Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)

Summary

Hepatitis B Virus Antibody Booster Program

Timeline

Start

2009-09

Primary completion

2011-03-11

Completion

2011-03-11

Outcome

Missed primary endpoint

Stopped: “Prematurely terminated due to failure to meet study objectives.”

registry Schedule 1- Standard Dose Primary Vaccination Series vs Schedule 2 - High Dose Primary Vaccination Series; p = 0.96; t-test, 2 sided NCT01311674 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Hepatitis B vaccine	Vaccine	20 ug	—
Subject	Hepatitis B vaccine	Vaccine	40 ug	—

Indications

No indication recorded.